- Nivolumab+bevacizumab is safe and tolerable in patients with relapsed ovarian cancer.
- Women with platinum-sensitive disease demonstrated a higher objective response rate (ORR).
Why this matters
- Single-agent PD-1/PD-L1 therapy has limited activity in ovarian cancer.
- Alternative immunotherapy combinations should be explored in the platinum-resistant setting.
- Phase 2 study of 38 women with relapsed epithelial ovarian cancer who experienced recurrence within 12 months of their last platinum-based therapy received nivolumab+intravenous bevacizumab.
- PD-L1 testing (n=36):
- Funding: Bristol-Myers Squibb.
- 18 patients had platinum-resistant and 20 had platinum-sensitive disease.
- Confirmed response was reported in 11 patients (ORR, 28.9%; 95% CI, 15.4%-45.9%); 1 additional patient had an unconfirmed response.
- 10 responses occurred in
- ORR was 40.0% in platinum-sensitive and 16.7% in platinum-resistant patients.
- Median PFS was 8.1 (95% CI, 6.3-14.7) months.
- Median duration of response was longer in platinum-resistant disease (12.3 vs 5.6 months), but PFS was shorter (5.3 vs 9.4 months).
- Overall clinical benefit rate (response+stable disease >24 weeks) was 55.3%.
- 89.5% of patients reported ≥1 treatment-related adverse event (grade ≥3, 23.7%).
- Single group.